NNNN - Company ID 0001982708
The table below shows Anbio Biotechnology's balance sheet line items across its last 2 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash & equivalents | $7.77M | $11.76M |
| Short-term investments | $4.13M | - |
| Receivables | $3.66M | $1.06M |
| Inventory | - | - |
| Total current assets | $30.24M | $18.53M |
| Property, plant & equipment | - | - |
| Goodwill | - | - |
| Total assets | $30.24M | $18.92M |
| Accounts payable | $0.00 | $1.63M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current liabilities |
| $87.84K |
| $1.73M |
| Long-term debt | - | - |
| Total liabilities | $87.84K | $1.73M |
| Retained earnings | $23.58M | $17.17M |
| Total equity | $30.16M | $17.19M |